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Abstract
Background—Aspirin reduces myocardial infarction but increases gastrointestinal bleeding.
Proton pump inhibitors (PPIs) may reduce upper gastrointestinal bleed. We estimate the cost-
utility of aspirin treatment with or without PPI for coronary heart disease (CHD) prevention
among men at different risks for CHD and gastrointestinal bleed.
Methods—We updated a Markov model to compare costs and outcomes of low-dose aspirin+PPI
(omeprazole 20-mg daily), low-dose aspirin alone, or no treatment for CHD prevention. We
performed lifetime analyses in men with different risks for cardiovascular events and
gastrointestinal bleed. Aspirin reduced nonfatal myocardial infarction by 30%, increased total
stroke by 6%, and increased gastrointestinal bleed risk 2-fold. Adding PPI reduced upper
gastrointestinal bleed by 80%. Annual aspirin cost was $13.99; generic PPI was $200.
Results—In 45-year-old men with 10-year CHD risk of 10% and 0.8/1,000 annual
gastrointestinal bleed risk, aspirin ($17,571 and 18.67 quality-adjusted life years [QALYs]) was
more effective and less costly than no treatment ($18,483 and 18.44 QALYs). Compared with
aspirin alone, aspirin+PPI ($21,037 and 18.68 QALYs) had an incremental cost/QALY of
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$447,077. Results were similar in 55- and 65-year-old men. The incremental cost/QALY of
adding PPI was less than $50,000/QALY at annual gastrointestinal bleed probabilities greater than
4–6/1,000.
Conclusion—Aspirin for CHD prevention is less costly and more effective than no treatment in
men over 45 with greater than 10-year, 10% CHD risks. Adding PPI is not cost-effective for men
with average gastrointestinal bleed risk but may be cost-effective for selected men at increased
risk for gastrointestinal bleed.
INTRODUCTION
The value of aspirin for primary prevention in men depends on trade-offs between its ability
to reduce nonfatal myocardial infarction and its potential to increase risk of hemorrhagic
stroke and extracranial (primarily gastrointestinal) bleeding.1 Although the increased risk of
hemorrhagic stroke cannot be mitigated, risk of upper gastrointestinal bleeding can be
reduced by acid suppressive therapy.2,3 A recent model suggests that the addition of generic,
low-cost omeprazole in patients aged 65 years and older using aspirin for secondary
prevention may be cost-effective due to its impact on reducing serious gastrointestinal
adverse events.4
Our previous modeling has found aspirin to be cost-effective for primary prevention in men
with increased coronary heart disease (CHD) risk but used relatively crude measures of
gastrointestinal bleed.5 Men were assumed to have a fixed excess rate of gastrointestinal
bleed with aspirin, with estimates of excess risk drawn from randomized trials of aspirin that
enrolled somewhat selected populations. Recent data from large observational cohort studies
have found higher rates of gastrointestinal bleed and larger relative risks (approximately 2.0)
associated with aspirin use.6 In addition, recent meta-analysis from the Antithrombotic
Trialists’ Collaboration suggested that gastrointestinal bleed risk from aspirin increased with
other CHD risk factors.7 Previous models also have not modeled the risk of fatal
gastrointestinal bleed. Although fatal bleeds from aspirin are rare,7 such an outcome should
be considered in order to provide conservative estimates of aspirin’s net effect. Finally, to
our knowledge, no primary prevention models have examined the effectiveness and cost-
effectiveness of routine use of gastrointestinal prophylactic agents to mitigate aspirin-related
risk of gastrointestinal bleed.
We sought to examine the cost-effectiveness of aspirin with and without the addition of
routine use of proton pump inhibitors (PPIs) for primary CHD prevention in men with a
range of underlying CHD and upper gastrointestinal bleed risks.
METHODS
Overview and Model Structure
We updated a previously developed a Markov model, programmed in Microsoft Excel5,8 to
examine the costs and outcomes of primary prevention treatment with aspirin alone or
aspirin plus PPI (aspirin+PPI) for men (see Appendix Figure A-1).
In the model, men begin treatment in the healthy state and transition through the model
annually. In each cycle, men remain in the healthy state; progress to initial, nonfatal
cardiovascular events such as angina, myocardial infarction, or stroke; have upper
gastrointestinal bleed; or die. Men who have cardiovascular events are assumed to stay in
the subacute state for the remainder of that cycle then enter a post-event health state where
they receive optimal secondary prevention. Because we are interested in primary prevention,
we did not simulate or examine the additional treatment course of patients after primary,
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nonfatal events. Instead, we assigned them an increased risk for mortality, increased costs,
and decreased utilities, using data from published literature on the average experience of
patients after an initial event.
Men who have gastrointestinal bleed discontinue aspirin use but do not receive PPIs if they
are not in the aspirin+PPI arm. They then enter a post-event health state where they progress
though the model as healthy men. However, these men are at greater risk for subsequent
gastrointestinal bleed.6
Men were followed for the remainder of their lifetimes to estimate costs, cardiovascular and
adverse events, life-years, and quality-adjusted life-years (QALYs). Efficacy data were
taken from published literature. Resource use and costs were drawn from published
literature and standard United States (US) costing sources and updated to 2009 dollars. The
analysis was performed from a third-party payer perspective. All costs and outcomes were
discounted at 3% per annum.
Patient Population
Men in the base-case analysis were assumed to be healthy, middle-aged men with starting
age of 45 years, no history of CHD events, and 10%, 10-year CHD risk (e.g., systolic blood
pressure 120, total cholesterol 220, high-density lipoprotein 30, nonsmoker, and no
diabetes).
Comparators
Men in the aspirin arm received 81 mg of generic aspirin daily. Patients taking aspirin+PPI
were treated with combination of aspirin as 81mg daily and generic omeprazole 20 mg daily.
We did not consider use of other CHD preventive strategies (smoking cessation,
hypertension treatment, or statin use) in this analysis, nor did we examine the effect of
aspirin in patients with diabetes or previous cardiovascular events. Treatment efficacy was
based on actual effects observed in clinical trials; we did not model effects of different levels
of adherence.
Model Parameters
Baseline Event Probabilities—Baseline risks of initial CHD events (myocardial
infarction, angina, and CHD death) and stroke were drawn from Framingham risk equations,
using hypothetical scenarios of nonsmoking adults without diabetes and with different sets
of other risk factors.9 We examined scenarios for men aged 45, 55, and 65 years with up to
six risk levels: 2.5%,5.0%, 7.5%, 10.0%, 15.0%, and 25.0%. Assuming an exponential
distribution, these 10-year risks were translated into annual, event-related transition
probabilities. These probabilities were allowed to change annually to reflect increasing CHD
and stroke risk over the time horizon of the analysis.
Age-dependent, noncardiovascular mortality was estimated from National Vital Statistics
life tables.10 Probabilities were adjusted as the cohort aged over the analysis time horizon.
Baseline risk of upper gastrointestinal bleed (not taking aspirin) was obtained from
Hernandez-Diaz et al.6 Annual risks were estimated as 0.0008, 0.0024, 0.0024, and 0.0036
for men aged 45, 55, 65, and over 65 years, respectively.6 In the model, a man starts with the
baseline gastrointestinal bleed risk for his age and his gastrointestinal bleed risk increases as
he ages.
Treatment Efficacy—The relative risks as drawn from published meta-analyses and
clinical trials are presented in Table 1. Aspirin was assumed to reduce men’s risk of nonfatal
myocardial infarction by 30%, CHD death by 13%, and to have no effect on angina. It
Earnshaw et al. Page 3













increased the combined risk of stroke (ischemic and hemorrhagic considered together) by
6%.11 More recent gender-specific analyses have found similar estimates for men.12 We did
not model the effect of aspirin on stroke-related mortality or on initial use of
revascularization procedures. The changes in each parameter were tested extensively in
sensitivity analyses.
PPI’s primary benefit was assumed to be an 80% reduction in upper gastrointestinal bleed
(i.e., occurrence of hospitalization due to gastrointestinal bleed) (relative risk [RR]: 0.20;
range: 0.10, 0.90), based mainly on one small randomized controlled trial in patients at high-
risk for gastrointestinal bleed.3,13 The efficacy of combination use of aspirin+PPI was
assumed to be independent: PPIs added no additional benefit and did not reduce the benefit
of aspirin for avoiding CHD events. We did not assume any direct adverse effects from
PPIs, nor did we include benefits of PPIs for treating symptomatic conditions such as
dyspepsia or reflux; our analysis applied to men without symptomatic upper gastrointestinal
conditions, thus we assumed that patients would adopt such treatments equally in both
groups if they became symptomatic.
All men who survived an initial CHD event received optimal secondary prevention
including aspirin, or alternate antiplatelet agents if they were not able to tolerate aspirin. The
effect of optimal treatment after initial events was the same between groups in the model.
Adverse Effects—Aspirin increased stroke risk by 6%.11 Increase in gastrointestinal
bleed risk in aspirin users with and without history of gastrointestinal bleed was 10.0 and
2.0, respectively.6 Although some data suggested no increased risk of fatal gastrointestinal
bleed with low-dose aspirin,7 we conservatively assumed a risk of gastrointestinal bleed
mortality of 1 out of 1,000 patients, and we tested a range of values in sensitivity analyses.
Men who had adverse effects were assumed to stop the offending agent and were not placed
on alternate agents for primary prevention.
Mortality—The effect of optimal secondary prevention on all-cause mortality was
estimated as RRs after initial cardiovascular events (Table 1), drawn from population-based
meta-analyses and from mortality in US life tables.14,15
Costs—Costs are presented in Table 2 and include outpatient physician visits, events, and
drug costs. Costs were similar to those in our previous analyses5,8 and updated to 2009 US
dollars using the Medical Consumer Price Index.18 Additional cost details are presented in
the Appendix.
Utilities—The utilities for the model were drawn from the literature.5,8 In most cases, they
were estimated using time trade-off techniques in original studies (see Table 2 and Appendix
Table A-1). Where no data existed, we made estimates and examined a wide range of values
in sensitivity analyses.
Outcome Measures
The model estimated the following outcomes: number of myocardial infarctions, strokes,
and gastrointestinal bleed events; costs; total costs; patient survival (life-years); QALYs; and
the incremental cost per QALY gained.
We examined the effect of treatment on different 10-year CHD risk levels (2.5%, 5.0%,
7.5%, 15.0%, and 25.0%), different model time horizons (5 year, 10 year, or lifetime), and
different starting ages (45, 55, and 65 years). Younger (under 45 years) and older (over 75
years) starting ages were not examined because sufficient treatment efficacy data were not
available.
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To test the robustness of model assumptions and specific parameters, we examined the
effect of changing several parameters in one-way sensitivity analyses. Parameters analyzed
included the relative risk of myocardial infarction, stroke, and CHD death for patients on
aspirin; increase in baseline risk of gastrointestinal bleed; relative risk of gastrointestinal
bleed, given treatment with aspirin, PPI, or aspirin+PPI; relative risk of cardiovascular death
with optimal secondary prevention; increase in mortality due to hemorrhagic stroke and
gastrointestinal bleed; costs of events and treatment; and utility weights for each health state.
The effect of varying individual parameters was examined using plausible ranges of values
(Table 1) from the literature, where 95% confidence intervals (CIs) were available, or by
varying the estimates by 20% in each direction.
In addition to one-way sensitivity analyses, we performed probabilistic sensitivity analysis
(second-order Monte Carlo simulation). The parameters varied in these analyses were
similar to those in one-way sensitivity analysis. We assumed that parameter estimates
followed a gamma distribution for all relative risks of events, increases in gastrointestinal
bleed, and increases in mortality, health-state costs, and drug costs. A beta distribution was
assumed for all health-state utilities. Analyses were run 10,000 times in order to capture
stability in results. Scatter plots were developed to represent uncertainty, and cost-
effectiveness acceptability curves were created.
RESULTS
Base Case
For 45-year-old men with 10-year, 10% CHD risk and annual gastrointestinal bleed risk of
8/10,000, men on aspirin gained more QALYs in their remaining lifetime than men on no
treatment (18.67 vs. 18.44). Treating with aspirin also was less costly ($17,571) over a
man’s remaining lifetime than no treatment ($18,483). Men on aspirin+PPI gained more
QALYs (18.68) but incurred higher costs ($21,037) than men assigned to aspirin alone. As a
result, the incremental cost per QALY with aspirin+PPI compared with aspirin alone was
$447,077, suggesting that addition of PPI prophylaxis was not cost-effective.
Aspirin remained more effective and less costly than no treatment at 5% 10-year CHD risk
and above (Table 3). However, across CHD risks levels, aspirin+PPI remained expensive
compared with aspirin alone. The patterns were similar for 55- and 65-year-old men with
base-case gastrointestinal bleed risk of 24/10,000 (Table 4). Shorter time horizons (5, 10,
and 20 years) had no appreciable effect on the cost-effectiveness of aspirin alone and led to
even higher costs per QALY gained with aspirin+PPI.
Effect of Gastrointestinal Bleeding Risk
We examined the effects of men’s baseline risk of gastrointestinal bleed on the incremental
cost per QALY (Figure 1). In 45-year-old men with 10%, 10-year CHD risk, aspirin
compared with no treatment remained cost-saving and cost-effective until a man’s risk of
gastrointestinal bleed was greater than 5%. Although use of aspirin+PPI is expensive, the
incremental cost per QALY of aspirin+PPI versus aspirin alone is less than $50,000 when
annual gastrointestinal bleed risk is 4/1000 and cost-saving when gastrointestinal bleed risk
is greater than 7/1,000.
In 55- and 65-year-old men, the incremental cost per QALY of aspirin+PPI was less than
$50,000 when baseline gastrointestinal bleed risk increased as little as 2- to 3-fold above
base case (Appendix Figures A-2 and A-3). Overall, as gastrointestinal bleed risk increased,
the incremental cost per QALY of aspirin+PPI compared with aspirin alone was lower in
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younger men because they received cardiovascular benefits of aspirin over longer periods of
time (their lifetime).
Sensitivity Analyses
One-Way Sensitivity Analysis—Sensitivity analyses (Figure 2) showed that the cost-
effectiveness of aspirin compared with no treatment was robust to changes to all key
parameters within their plausible ranges. In particular, aspirin’s effect on nonfatal
myocardial infarction and CHD deaths had minimal impact on cost-effectiveness of aspirin
compared with no treatment. The cost-effectiveness of aspirin+PPI compared with aspirin
alone was sensitive to changes in gastrointestinal bleed-related parameters, such as aspirin
and aspirin+PPI’s relative effect on gastrointestinal bleed and utility of gastrointestinal bleed
(Figure 2b). However, within their plausible ranges, the incremental costs per QALY
remained in the $300,000 to $800,000 range. Incremental cost per QALY also was
insensitive to changes in risk of mortality due to gastrointestinal bleed until risk increased to
more than 1% (Appendix Figure A-4). We found that lowering the annual cost of PPIs to
under $50 (less than 20% of the base-case value) resulted in an incremental cost per QALY
of less than $100,000 for aspirin+PPI compared with aspirin alone; in contrast, at higher PPI
prices, aspirin was not cost-effective even for those at increased bleeding risk (Appendix
Figure A-5). Two-way sensitivity analyses that used newer meta-analysis with gender-
specific RRs of stroke (RR: 1.13; 95% CI: 0.96, 1.33) and MI (RR: 0.68; 95% CI: 0.54,
0.86) for aspirin showed that results remained unchanged (Appendix Table A-2).12
Probabilistic Sensitivity Analysis—We performed probabilistic sensitivity analyses to
examine the collective effect of parameter uncertainty (Figure 3). We observed incremental
costs per QALY of aspirin versus no treatment of less than $50,000 in 99.8% and 97.4% of
men aged 45 and 65 years, respectively. Compared with aspirin alone, incremental costs per
QALY of aspirin+PPI versus aspirin alone was less than $50,000 for 0.0% and 0.5% of the
time in 45- and 65-year-old men, respectively. However, incremental costs per QALY
crossed all four quadrants. Scatter plots and cost-effectiveness acceptability curves for men
aged 45 and 65 years with 10-year, 10% CHD risk are presented in Appendix Figures A-6
through A-8.
DISCUSSION
Decisions about which men should receive low-dose aspirin for CHD prevention involves
trade-offs between aspirin’s adverse effects and its beneficial effects. Some investigators
have attempted to estimate the benefit/harm trade-off by determining relative risks of each
event through meta-analyses and then informally “weighing up” likely benefits and
disadvantages for patient populations with different CHD and gastrointestinal bleed risk
profiles.7,11 Such informal processes, however, are difficult to perform because main
outcomes of interest (stroke, myocardial infarction, and gastrointestinal bleed) each have
different health effects.1 We and others have attempted to rigorously model effects of aspirin
and have found aspirin to be cost-saving or cost-effective for men with moderate and greater
CHD risk levels.5,19
Recent data, however, have suggested that gastrointestinal bleed risk may be higher than
levels observed in clinical trials6 and that patients with elevated CHD risk may be at higher
risk for gastrointestinal bleed.7 Some decision makers have advocated using PPI therapy
concurrently with aspirin to reduce the risk of bleeding, after considering clinical trial
evidence from patients at high risk for gastrointestinal bleed3 and decision-analytic
modeling studies suggesting PPI use is beneficial in secondary CHD prevention.4 In this
updated analysis, we attempted to address some of these concerns and better estimate the net
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effect of aspirin with or without PPI for patients at different levels of CHD and
gastrointestinal bleed risk. In modeling an age-dependent gastrointestinal bleed risk, we
found that aspirin remained cost-saving compared with no treatment across a wide range of
CHD and gastrointestinal bleed risk levels for men aged 45 to 65 considering initiation of
aspirin. We also found that adding generic PPI therapy to aspirin for all men was not cost-
effective in most cases because risk of gastrointestinal bleed was not large enough to
warrant routine prophylaxis. However, under favorable assumptions about PPI efficacy and
pricing, adding PPI when gastrointestinal bleed risk is 5/1,000 per year for men aged 45 (and
slightly higher for older men), had a favorable cost-effectiveness ratio of $22,000 per QALY
gained. This represents about a 4-fold increase in baseline bleeding risk. Assuming a
branded cost of a PPI at $1,951 per year, a man’s gastrointestinal bleed risk would need to
be 6.7/100 per year (over 10 times higher than our base case) in order for the addition of a
PPI to be cost-effective in a man with the same CHD risk.
Our analysis highlights that some men who are at increased gastrointestinal bleeding risk
may benefit from adding PPI when using low-dose aspirin for CHD risk reduction.
Providers should assess the risk of gastrointestinal bleeding by considering the patients age,
prior history of gastrointestinal bleeding, and use of other medications that increase bleeding
risk (Table 5).6,20 For example, a 55-year-old man taking naproxen (a nonsteroidal anti-
inflammatory drug) for arthritis and a selective serotonin reuptake inhibitor for depression
would have a 4.8 per 1000 annual risk of bleeding and would be a reasonable candidate for
PPI if those medications could not be discontinued.20
Our findings were robust across a range of CHD risk levels and were not affected by factors
such as a reduced relative benefit of aspirin on nonfatal CHD or an increased risk of fatal
gastrointestinal bleed. In addition, results were insensitive to changes in aspirin risk of MI
and stroke, as obtained from a gender-specific meta-analysis.12 However, if PPI’s actual
gastrointestinal bleed risk reduction is much lower than the modeled effect or its pricing is
much higher than $200 per year, the benefits of adding PPI to aspirin will be small or
negligible, even for those at increased risk.
Other modeling studies have reached similar results when considering the effect of aspirin in
men at different CHD risk levels. Specifically, Greving and colleagues developed a Markov
model to evaluate the cost-effectiveness of aspirin for primary prevention in the
Netherlands.19 They used a 10-year time horizon and drew baseline event probabilities and
costs from Dutch data. Relative risk reductions were based on available meta-analyses and
were similar to those used in our model. Utility of taking aspirin was assumed to be 0.999,
and annual cost of aspirin was €97, to account for pharmacist and practitioner prescribing
and dispensing costs. They found aspirin to be cost-effective (incremental cost per QALY <
€20,000) for men 55 to 75 years old with 10-year CHD risk over 10%. However, the study
found an incremental cost per QALY of greater than €100,000 for men younger than 55
years old with CHD risk of between 5% and 6%. Results were sensitive to aspirin cost
assumptions and disutility associated with aspirin use. Lamotte and colleagues developed
models of effect of aspirin for primary prevention and reached conclusions similar to our
current and previous analyses.21 None of the previous models, however, have examined the
cost-effectiveness of adding routine PPI plus aspirin compared with aspirin alone or no
treatment for primary prevention. Our study has a number of limitations. Given the lack of
trials of PPIs in aspirin users without prior history of ulcer bleeding, we estimated benefit of
PPI therapy among aspirin users on the basis of a single, randomized controlled trial among
high-risk users.3 This estimate is supported by a large body of observational data that
informed the recommendation that PPIs be given to patients with high gastrointestinal bleed
risk.2
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We used data on upper gastrointestinal bleeding for our analysis; aspirin may increase the
risk of lower gastrointestinal bleeding, as well as other extracranial bleeds, but we did not
model these directly. However, aspirin remains cost-effective compared with no therapy,
even if the annual risk of gastrointestinal bleeding is 5%, so not including other, less
common sources of gastrointestinal bleeding is unlikely to change our results.
Although PPI therapy may increase the risk of various adverse clinical outcomes among
long-term users, we did not include such effects in our model. Specifically, observational
studies have demonstrated a modest but significantly increased risk for community-acquired
pneumonia as well as enteric infections, particularly involving Clostridium difficile.22 In
addition, high-dose, twice-daily PPI therapy has been proposed to increase risk of
osteoporotic fractures. Existing data on these effects remain controversial, and robust data to
model their risk are limited.2,23,24
CONCLUSIONS
This updated analysis supports the role of aspirin for primary prevention of CHD events in
middle-aged men across a range of CHD and gastrointestinal bleeding risk levels. Increased
risk of gastrointestinal bleeding does not reduce aspirin’s net benefit until gastrointestinal
bleeding risk becomes quite high, such as the level seen in men with previous
gastrointestinal bleeds. Adding PPI therapy does not appear to be cost-effective for those
patients at low or average risk for gastrointestinal bleed but may be valuable for those with a
gastrointestinal bleed risk over 4/1,000 per year. Further efforts to include gastrointestinal
bleeding risk assessment when prescribing low-dose aspirin for CHD protection are
warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Effect of Change in Baseline Gastrointestinal Bleed Risk in a 45-Year-Old Man With a
10-Year, 10% CHD Risk
Figure 1a: Aspirin Versus No Treatment
Figure 1b: Aspirin+PPI Versus Aspirin Alone
CHD = coronary heart disease; PPI = proton pump inhibitor; QALY = quality-adjusted life-
year.
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Figure 2. One-Way Sensitivity Analysis: 45-Year-Old Man With a 10-Year, 10% CHD Risk
Figure 2a: Aspirin Versus No Treatment
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Figure 2b: Aspirin+PPI Versus Aspirin Alone
CHD = coronary heart disease; CVD = cardiovascular disease; HS = health state; MI =
myocardial infarction; PPI = proton pump inhibitor; QALY = quality-adjusted life-year.
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Figure 3. Probabilistic Sensitivity Analysis: 45-Year-Old Man With a 10-Year, 10% CHD Risk
Figure 3a: Aspirin Versus No Treatment
Figure 3b: Aspirin+PPI Versus Aspirin Alone
CHD = coronary heart disease; PPI = proton pump inhibitor; QALY = quality-adjusted life-
year.
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Table 1




Relative Risk of Events
Aspirin Alone
Angina 1.00 (95% CI: 0.80, 1.20) Assumption
Stroke 1.06 (95% CI: 0.91, 1.24) 11
Myocardial infarction 0.70 (95% CI: 0.62, 0.79) 11
CHD death, males 0.87 (95% CI: 0.70, 1.09) 16
Gastrointestinal bleed (no history of gastrointestinal bleed) 2.00 6
Gastrointestinal bleed (with history of gastrointestinal bleed) 10.00 6
Aspirin+PPI
Gastrointestinal bleed 0.20 (95% CI: 0.10, 0.90) 13
Mortality
Proportion of hemorrhage strokes that are fatal 0.33 (95% CI: 0.10, 0.50) Expert clinical opinion
Death due to gastrointestinal bleed 0.001 (range: 0.00001, 0.1) Expert clinical opinion
Increase in Risk of Mortality
After Initial CHD Event
After myocardial infarction 3.7 (95% CI: 3.0, 4.7) 14
After angina 3.0 (95% CI: 2.1, 4.2) 14
After stroke 2.3 (95% CI: 1.0, 4.6) 15
Reduction of death due to aspirin therapy after a CV event 0.85 (95% CI: 0.80, 0.90) 17
CHD = coronary heart disease; CI = confidence interval; CV = cardiovascular; PPI = proton pump inhibitor.
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Table 2
Cost and Utility Parameters, Values, and Plausible Ranges














Post myocardial infarction $3,590
Utility Data
Healthy 1.000
Gastrointestinal bleed 0.94 (95% CI: 0.880, 1.000)
Post gastrointestinal bleed 1.000
Dyspepsia 0.996 (95% CI: 0.997, 1.000)
Angina 0.929 (95% CI: 0.923, 1.000)
Post angina 0.997 (95% CI: 0.997, 1.000)
Stroke 0.610 (95% CI: 0.480, 0.830)
Post stroke 0.830
Myocardial infarction 0.870 (95% CI: 0.820, 0.920)
Post myocardial infarction 0.910 (95% CI: 0.860, 0.960)
Healthy 1.000
CI = confidence interval; PPI = proton pump inhibitor.
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Table 4
Effect of Time Horizon and Age on the Cost-effectiveness of Aspirin and Aspirin+PPI in Men With 10-Year,
10%, CHD
Time Horizon
Age (Years) 5 Years 10 Years 25 Years Lifetime
Aspirin vs. No Treatment
45 More effective, less costly More effective, less costly More effective, less costly More effective, less costly
55 More effective, less costly More effective, less costly More effective, less costly More effective, less costly
65 $1,120 More effective, less costly More effective, less costly $50
Aspirin+PPI vs. Aspirin Alone
45 $2,513,270 $1,974,339 $1,010,770 $447,077
55a $702,561 $531,451 $250,420 $175,641
65 $712,499 $537,048 $290,968 $276,984
CHD = coronary heart disease; PPI = proton pump inhibitor; QALY = quality-adjusted life year.
a
Incremental cost per QALY from 55 to 65 years of age reduces, although the risks of myocardial infarction and CHD deaths increase, because the
cost of the PPI outweighs the benefit of including the PPI.
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Table 5











Less than 60 0.8 1.9 3.2 4.8
60–69 2.4 5.8 9.6 14.4
70–79 3.6 8.6 14.4 21.6
80–89 6.0 14.4 24.0 36.0
NSAID = nonsteroidal anti-inflammatory drug; SSRI= selective serotonin reuptake inhibitor.
a
From Hernandez-Diaz et al.6
b
Odds ratio = 2.4.20
c
Odds ratio = 6.0.20
The risk in this table is for men with no ulcer-related bleeding and assumes that the relative risks approximate the odds ratios and that the relative
risks are independent. For estimating gastrointestinal bleeding risk for patient with previous history of uncomplicated ulcer, multiply by 6; multiply
by 10 for history of complicated ulcer.
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